| T6982 |
SGI-7079
|
1239875-86-5
|
98%
|
|
|
SGI-7079 is a new selective Axl inhibitor. SGI-7079 can be a dose-dependent manner inhibited growth of tumors. It is also a potential therapeutic target for EGFR...
|
| T2S0837 |
Astragalus Polysacharin
|
|
98%
|
|
|
2-(Chloromethyl)-4-(4-nitrophenyl)thiazole is a natural product derived from Astragalus propinquus.2-(Chloromethyl)-4-(4-nitrophenyl)thiazole exhibits anticancer...
|
| T76864 |
Enapotamab
|
1912423-61-0
|
98%
|
Enapotamab
|
|
Enapotamab is an AXL/UFO-related antibody that can be used to synthesize antibody-drug couplings (Enapotamab Vedotin).
|
| T76776 |
Emactuzumab
|
1448221-67-7
|
98%
|
|
|
Emactuzumab(RG 7155) is a monoclonal antibody against colony-stimulating factor-1 receptor targeting tumor-associated macrophages (TAMs) Emactuzumab has antitumo...
|
| T7425 |
RU-301
|
1110873-99-8
|
98%
|
|
|
RU-301 is a novel pan-tam inhibitor
|
| T21302L |
UNC 569 hydrochloride
|
|
100%
|
|
|
UNC 569 hydrochloride is a reversible and ATP-competitive inhibitor of Mer with an IC50 of 2.9 nM and a Ki of 4.3 nM. UNC 569 hydrochloride inhibits Axl and Tyro...
|
| T21302L |
UNC 569 hydrochloride
|
|
100%
|
|
|
UNC 569 hydrochloride is a reversible and ATP-competitive inhibitor of Mer with an IC50 of 2.9 nM and a Ki of 4.3 nM. UNC 569 hydrochloride inhibits Axl and Tyro...
|
| T5164 |
Cabozantinib hydrochloride
|
1817759-42-4
|
97.09%
|
|
|
Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6 nM...
|
| T3274 |
S49076
|
1265965-22-7
|
97.4%
|
|
|
S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs.
|
| T6907 |
NPS-1034
|
1221713-92-3
|
97.86%
|
|
|
NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.
|
| T7379 |
2-D08
|
144707-18-6
|
98%
|
|
|
2-D08 is a synthetic flavone that inhibits sumoylation, also inhibits Axl with an IC50 of 0.49 nM.2-D08 showed anti-aggregatory and neuroprotective effect.
|
| T6269 |
Bemcentinib
|
1037624-75-1
|
98%
|
|
|
Bemcentinib (R428) is a selective inhibitor of Axl (IC50: 14 nM) and has been investigated for the treatment of NSCLC.
|
| T71973 |
Gilteritinib hemifumarate
|
1254053-84-3
|
98.07%
|
|
|
Gilteritinib hemifumarate (ASP2215 hemifumarate) is a potent ATP-competitive dual FLT3 (IC50: 0.29 nM) and AXL (IC50: 0.73 nM) inhibitor for the treatment of rel...
|
| T6120 |
Pralatrexate
|
146464-95-1
|
98.12%
|
|
|
Pralatrexate (10-Propargyl-10-deazaaminopterin) is a folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carr...
|
| T2620 |
G-749
|
1457983-28-6
|
98.32%
|
|
|
G-749, a new-type FLT3 inhibitor, exhibits effective and sustained inhibition of the FLT3 wild type and mutants.
|
| T8327 |
ONO-7475
|
1646839-59-9
|
98.33%
|
|
|
ONO-7475 is an inhibitor with high specificity for anexelekto and MER tyrosine kinase
|
| T6121 |
Tepotinib
|
1100598-32-0
|
98.35%
|
|
|
Tepotinib (EMD-1214063) is an inhibitor of MET tyrosine kinase with potential antineoplastic activity.
|
| T2005 |
Dubermatinib
|
1341200-45-0
|
98.65%
|
|
|
Dubermatinib (TP0903) is a potent and selective Axl kinase inhibitor.
|
| T1797 |
Cabozantinib S-malate
|
1140909-48-3
|
98.87%
|
|
|
Cabozantinib S-malate (XL184) is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with pot...
|
| T4349 |
Sitravatinib
|
1123837-84-2
|
98.9%
|
|
|
Sitravatinib (MGCD516) (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Ax...
|
